MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Bio-IT World
August 13, 2002
Judith S. Hurwitz
Software for Life Sciences: A Few Requests At the core of the life science revolution is IT. There is a discrepancy, however, between the emerging technology requirements and the preparedness of the technology industry to meet the needs of this market. mark for My Articles similar articles
Chemistry World
August 23, 2012
Simon Campbell
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. mark for My Articles similar articles
Inc.
May 1, 2002
Kenneth Klee
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... mark for My Articles similar articles
Bio-IT World
December 10, 2002
Jim Hall
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. mark for My Articles similar articles
Chemistry World
February 2012
Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment. mark for My Articles similar articles
Bio-IT World
September 2006
Mike May
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. mark for My Articles similar articles
Finance & Development
March 2011
Lora & Pages
Face-to-Face with Productivity It is not lack of investment but inefficient production that holds back Latin American incomes. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2011
George Baeder
China's Future in Bioscience Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse? mark for My Articles similar articles
Chemistry World
December 8, 2011
Sarah Houlton
Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2007
Walter Armstrong
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. mark for My Articles similar articles
Bio-IT World
April 2006
Kevin Davies
Microsoft Forges BioIT Alliance The software giant's fledgling alliance aims to bring together companies from a cross-section of the industry -- from biotech and Big Pharma to equipment manufacturers and software developers -- to collaborate on technology that will speed drug discovery. mark for My Articles similar articles
Reactive Reports
Issue 57
Interview with Andrew Lemon With a background in Chemistry and a keen sense of business, this co-found of The Edge Software Consultancy helps global pharmaceutical companies increase the efficiency and productivity of their software tools. mark for My Articles similar articles
Investment Advisor
August 2006
S&P Mutual Fund Sector Focus: Health Care Funds Tired and Sluggish Big pharma names dominate most health care funds and these businesses are beset with problems. One of the best longer-term performers in this area, the $561-million Schwab Health Care Fund. mark for My Articles similar articles
Pharmaceutical Executive
January 21, 2014
Tim Powell
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? mark for My Articles similar articles
The Motley Fool
September 9, 2004
Charly Travers
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. mark for My Articles similar articles
Bio-IT World
November 2005
Charles Firneno
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value. mark for My Articles similar articles
Bio-IT World
September 2005
Kevin Davies
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. mark for My Articles similar articles
Knowledge@Wharton A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... mark for My Articles similar articles
Bio-IT World
June 2006
Michael A. Greeley
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. mark for My Articles similar articles
Investment Advisor
December 2005
Greg B. Scott
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
William Looney
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. mark for My Articles similar articles
Bio-IT World
March 10, 2003
Mark D. Uehling
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2009
Bank on IT Tough economic times call for a bold approach to evolving information technology solutions. mark for My Articles similar articles
Bio-IT World
October 2006
Thomas G. Morr
Eight Essential Elements for Commercial Success For life sciences companies both young and old, location is one of the critical success factors. With that in mind, here are eight essential considerations for life sciences executives when they are thinking of starting a business or opening a new location. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2008
RS Kumar
Evolving Clinical Trials Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in efficiency. mark for My Articles similar articles
IEEE Spectrum
January 2012
Philip E. Ross
Don't Let Innovation Languish The world's economy depends on innovation rates that are faster than they were for most of human history -- and faster than they are today. mark for My Articles similar articles
Bio-IT World
December 10, 2002
Malorye Branca
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. mark for My Articles similar articles
The Motley Fool
August 2, 2004
Charly Travers
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2006
Ron Feemster
Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials. mark for My Articles similar articles
The Motley Fool
November 16, 2006
Jim Fink
The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007. mark for My Articles similar articles
HBS Working Knowledge
November 13, 2006
Sean Silverthorne
Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business. mark for My Articles similar articles
The Motley Fool
April 4, 2009
Brian Orelli
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. mark for My Articles similar articles
The Motley Fool
May 5, 2009
Brian Orelli
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
Zhu Shen
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
Bill Drummy
Scared to Death The pharma industry's risk-aversion is risking its survival. Where did the courage to innovate go? mark for My Articles similar articles
Knowledge@Wharton
October 8, 2003
Biosciences: High Risk, High Reward, and the Potential for "Real Chaos" While bioscience researchers struggle to understand the workings of the human body, biotech managers and investors are searching for ways to better understand this complex and quickly evolving industry, according to Wharton faculty and lecturers. mark for My Articles similar articles
Bio-IT World
June 15, 2003
Bob Violino
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry mark for My Articles similar articles
Chemistry World
January 29, 2013
Laura Howes
Five green chemical feedstock projects launched The UK's Engineering and Physical Sciences Research Council has announced 10.7 million pounds, in combination with 1.1 million pounds from the Biotechnology and Biological Sciences Research Council, to fund five projects to develop new bio-based feedstocks for the chemical industry. mark for My Articles similar articles
Job Journal
August 8, 2004
Rich Heintz
Biotech's Winning Formula for Steady Job Growth Deep pockets are creating expanding opportunities and biotechnology is helping to put America back to work. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. mark for My Articles similar articles
BusinessWeek
October 20, 2003
Gary S. Becker
The Productivity Boom Is Just Warming Up In the past, productivity almost always fell during recessions because both labor and capital were underutilized as output sagged. But the apparent paradox of the past few years is that labor productivity has grown even more rapidly since 2000 than in the '90s. mark for My Articles similar articles
IndustryWeek
August 1, 2004
Tonya Vinas
Making Waves Dubbed the 'third wave' of biotechnology, after medicine and agriculture, industrial biotechnology is promising to reshape manufacturing. mark for My Articles similar articles
Bio-IT World
October 14, 2004
Robinson & Violino
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. mark for My Articles similar articles
Bio-IT World
April 2006
Laura Huckabee-Jennings
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed. mark for My Articles similar articles
Finance & Development
March 1, 2006
Baily & Farrell
Breaking Down Barriers to Growth Encouraging competition is key to reviving stalled industrial economies. mark for My Articles similar articles
The Motley Fool
April 24, 2007
Ryan Fuhrmann
Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors. mark for My Articles similar articles
The Motley Fool
June 21, 2005
Brian Gorman
Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note. mark for My Articles similar articles
The Motley Fool
January 20, 2011
Dan Caplinger
Value Investing Will Never Be the Same More value-oriented funds are buying traditional growth stocks. mark for My Articles similar articles
IndustryWeek
January 1, 2005
Patricia Panchak
Shaping the Future of Manufacturing A tour through manufacturing's recent history reveals clues of what's to come. mark for My Articles similar articles
The Motley Fool
December 20, 2007
Brian Orelli
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. mark for My Articles similar articles